Current treatments for childhood acute lymphoblastic leukaemia (ALL) are highly toxic. In this project Professor Enver and his team hope to identify drugs that target specific vulnerabilities of leukaemia cells and combine them together to effectively eradicate the leukaemia cells without harming normal cells.
Targeting RUNX/Core Binding Factor-dependency in relapsed and poor prognosis acute lymphoblastic leukaemia
Professor Tariq Enver
UCL Cancer Institute
London, WC1E 6BT
1 July 2017